Cochlear Limited (CHEOY)
| Market Cap | 4.80B -58.0% |
| Revenue (ttm) | 1.56B +1.3% |
| Net Income | 230.32M -6.8% |
| EPS | 3.51 -6.6% |
| Shares Out | n/a |
| PE Ratio | 20.83 |
| Forward PE | 20.22 |
| Dividend | 1.31 (3.56%) |
| Ex-Dividend Date | Mar 20, 2026 |
| Volume | 19,316 |
| Average Volume | 70,571 |
| Open | 36.59 |
| Previous Close | 36.64 |
| Day's Range | 36.25 - 36.59 |
| 52-Week Range | 31.82 - 105.60 |
| Beta | 0.24 |
| RSI | 30.09 |
| Earnings Date | Aug 18, 2026 |
About Cochlear
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories. The company was founded in 1981 and is headquartered i... [Read more]
Financial Performance
In fiscal year 2025, Cochlear's revenue was 2.34 billion, an increase of 4.81% compared to the previous year's 2.24 billion. Earnings were 388.90 million, an increase of 9.00%.
Financial numbers in AUD Financial StatementsNews
Dig Howitt’s week from hell a sign of the times for health giants
For decades Cochlear, CSL and ResMed could do no wrong. Those days are over, and a battery of issues has investors increasingly sceptical about their prospects.
Cochlear caught in market’s deadly crocodile roll
The hearing implant maker is fighting a high-stakes battle against market dark arts and an investor exodus that could trigger total upheaval in the boardroom.
MED-EL USA Presents Real World Clinical Insights to Support Tailored Hearing Solutions at the 2026 American Cochlear Implant Association Meeting
DURHAM, N.C.--(BUSINESS WIRE)-- #ACIA2026--Hearing implant leader MED-EL USA is announcing two upcoming symposia at CI2026, the annual meeting of the American Cochlear Implant Association (ACIA) in Ch...
Cochlear Shares Plunge 39% After Profit Guidance Cut
Cochlear Shares Plunge 39% After Profit Guidance Cut
Cochlear (COH) Faces Major Stock Drop Amid Weak Market Conditions
Cochlear (COH) Faces Major Stock Drop Amid Weak Market Conditions
Australia's Cochlear crashes 40% after flagging weak demand and Mideast war impact
Cochlear shares crashed nearly 41% on Wednesday in a record daily fall, after the Australian hearing implants maker slashed its forecast for annual earnings, citing weak trading conditions and uncert...
5 Reasons Cochlear Share Price Crashed 39% Today: Earnings Miss and Guidance Cut Shock Investors
SYDNEY — Cochlear Limited shares plunged as much as 41% on Wednesday, trading as low as $101.60 after the world's largest cochlear implant maker reported disappointing first-half 2026 results, lowered...
Cochlear Share Price Crashes 39% to $101.60 After Dismal HY26 Results and Guidance Cut
SYDNEY — Cochlear Limited shares plunged as much as 41% on Wednesday, trading as low as $101.60 after the world's leading cochlear implant maker reported disappointing first-half 2026 results, lowered...
Cochlear Lowers FY26 Underlying Net Profit Guidance
(RTTNews) - Cochlear (COH.AX) lowered its fiscal 2026 underlying net profit guidance to A$290-330 million, incorporating current exchange rates. Cochlear had previously disclosed to the market that it...
Bang, crash, wallop: Cochlear tanks on ‘staggering’ bad news
A 40 per cent share price drop is unprecedented for this big blue chip - there will be ramifications.
Cochlear dives to 10-year low on profit downgrade
The hearing implant maker’s shares cratered to the lowest level since April 2016 amid the Middle East conflict and plunging US sentiment.
Cochlear Transcript: Trading update
Lower sales and profit are driven by weak demand in developed markets, Middle East disruptions, and hospital system pressures. Strategic focus is on cost base reshaping, accelerating growth investments, and advocacy to elevate hearing loss as a healthcare priority. Guidance reflects ongoing uncertainty and a multi-year path to margin recovery.
ASX 200 LIVE: ASX falls; Cochlear sinks 36pc on outlook cut; Treasury Wine soars
Shares fall amid US-Iran tensions; Cochlear smashed on profit warning; Treasury Wine soars on restructure; Corporate Travel flags $222m revenue reversal; BHP ups copper guide. Follow live.
Cochlear North America Celebrates International Cochlear Implant Day with Announcement of 2026 Academic Scholarship Recipients
LONE TREE, Colo., Feb. 25, 2026 /PRNewswire/ -- In celebration of International Cochlear Implant Day, Cochlear North America is proud to announce the recipients of the 2026 Cochlear Academic Scholarsh...
Cochlear Earnings Call Transcript: H1 2026
First half results were impacted by the Nexa launch, leading to a 2% revenue decline and 17% net profit margin, with strong second half growth expected. FX headwinds and competitive pressures affected margins and share, but restructuring and growth initiatives are underway.
Cochlear Announces Availability of Nucleus Nexa System to US Military Veterans
LONE TREE, Colo., Jan. 8, 2026 /PRNewswire/ -- Cochlear, the global leader in implantable hearing solutions, is proud to announce that the groundbreaking Nucleus® Nexa® System is now available to elig...
MRI 3T Cochlear Implant Market Poised for 9.96% CAGR Growth, North America Leads
Ottawa, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The global MRI 3T cochlear implant market size is calculated at USD 902.78 million in 2025 and is expected to reach around USD 2101.54 million by 2034, growi...
MED-EL Cochlear Implant Becomes First FDA-Approved Option for Children Seven Months and Older
DURHAM, N.C.--(BUSINESS WIRE)-- #FDAapproval--FDA approves expanded indication for MED-EL cochlear implants for children seven months and older with bilateral sensorineural hearing loss.
Cochlear Transcript: AGM 2025
The AGM reviewed solid financial results, with sales and profit growth, increased dividends, and strong R&D investment. Board renewal, global expansion, and sustainability were emphasized, while shareholders raised questions on strategy, competition, and market risks.
Cochlear Earnings Call Transcript: H2 2025
Revenue grew 4% year-over-year with strong Cochlear implant and emerging market growth, but services declined 10% due to U.S. consumer hesitancy and a smaller eligible base. The Nexa system launch and continued R&D investment support a positive outlook, though China pricing and U.S. uncertainty remain headwinds.
Cochlear Launches World's First and Only Smart Cochlear Implant System
Upgradeable Firmware: The Cochlear™ Nucleus® Nexa™ System features upgradeable firmware on the implant – an industry first, allowing recipients to access future innovation through firmware updates. Sm...
Starkey and MED-EL Announce All-New DualSync Partnership to Advance Bluetooth Connectivity for Cochlear Implant Users
DURHAM, N.C.--(BUSINESS WIRE)-- #audiology--Driven by a shared commitment to advancing hearing health, global hearing technology leaders Starkey and MED-EL are bringing their exclusive collaboration t...
Cochlear introduces the Baha® 7 Sound Processor and Baha SoundBand™
NEW Baha® 7 Sound Processor: First in bone conduction to enable Bluetooth® LE Audio* and Auracast™ broadcast audio streaming capabilities1, 2. NEW Baha SoundBand ™ : Improved look and fitting options ...
Hearing Implants Global Strategic Business Report 2025: Market to Reach $4.9 Billion by 2030 - Increasing Adoption of Cochlear Implants Expands Opportunities
Dublin, March 12, 2025 (GLOBE NEWSWIRE) -- The "Hearing Implants - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Hearing Implants ...
Assessment of the $6.63 Billion Cochlear Implants Market, 2034: Emerging Markets, such as Asia-Pacific, Latin America and Africa, Present a Significant Growth Opportunity
Dublin, March 12, 2025 (GLOBE NEWSWIRE) -- The "Cochlear Implants Market - A Global and Regional Analysis: Focus on Patient Type, End User, and Region - Analysis and Forecast, 2024-2034" report has be...